Medindia

X

Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting

Friday, May 16, 2008 General News J E 4
Advertisement
SAN FRANCISCO, May 16 Velos, Inc., the recognized leaderand trusted resource for clinical trial management systems this week hosted aconstellation of prestigious academic medical centers, research institutionsand industry partners at its annual user group meeting in San Francisco. TheVelos eResearch system allows customers to internally and collaborativelymanage thousands of clinical trials.

Over 140 professionals, including representatives from institutions suchas Cleveland Clinic Foundation, Duke University, MD Anderson, UCLA, Universityof Miami, and University of Michigan, attended this week's meeting at SanFrancisco's Hyatt Regency Hotel. Also in attendance were representatives fromthe pharmaceutical and biotech industries. Such themes as collaboration,direct data capture, multi-site research network management, outcomesmeasurement, patient self-reporting, and financial management, were discussedthroughout the two-day session.

"We're delighted to see continued strong growth in the Velos customerbase," said John S. McIlwain, President and CEO of Velos. "Attendance againincreased more than 40 percent this year and approximately tenfold since ourfirst user group meeting in 2005. The company's success in managing thisgrowth is supported by the enthusiasm and passion of our customers. Thisyear's meeting has been highlighted by customer willingness to shareexperiences and accomplishments and to collaborate in adoptingstate-of-the-art clinical research system infrastructure. We believe that thisexceptional and growing customer base is increasingly positioned to move theindustry forward as a whole."

A South Korean delegation was an eager participant in the many sessions.South Korea is deploying the Velos eResearch system in an unprecedentedcountrywide initiative that allows seamless clinical trials collaboration andinformation sharing among all South Korean cancer centers.

Velos U.S. customers receive over 30 percent of extramural clinicalresearch funding from the National Institutes of Health, among the 100 largestsuch recipients -- the largest such share among clinical trial managementsystem software vendors. The National Cancer Institute grants approximately40 percent of its extramural funding to such Velos customers, also the largestsuch share. The Velos eResearch customer base includes 21 top 25* U.S.medical centers.

Speakers included representatives from the University of California Davis,Cleveland Clinic, Dartmouth University, Mary Crowley Cancer Centers,University of Miami, University of Michigan, and Northwestern University.Priti Sahai, MD, Velos Vice President of Product Development introduced arange of new system features, tools, and integrated product offerings,including Velos eResearch Version 8. "We were very pleased by the customerresponse to Version 8.0," observed Sahai. "It's gratifying to know that wecontinue to be on the right track and that our focus on product innovation ispaying off for our customers."

"The highly regarded research centers who are Velos customers provideessential support for much-needed improvements in the information model inclinical research," noted Amar Chahal, MD, Velos Co-Founder and Executive VicePresident. "These Velos customers have the knowledge, resources, and incentiveto facilitate positive change. We've witnessed these dynamics in action thisweek here in San Francisco."

About Velos

Velos is the trusted clinical trial management resource for investigators,sponsors and academic leaders throughout the U.S. Velos eResearch is deployedfor clinical research in all parts of the healthcare enterprise and supports abroad diversity of clinical departments and functional needs. The systemfundamentally improves the way data is collected, organized and shared. A pureInternet technology platform, Velos eResearch harnesses advanced powers of theInternet to en
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
International SOS Responds to Sichuan Earthquake
S
Pharmacopeia's First-in-Class Investigational Ther...